-
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Awarded BARDA Project NextGen (PNG) contract to advance GeoVax’s multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG…
-
GeoVax to Participate in Upcoming Investor Conferences in September
Atlanta, GA, September 3, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today…
-
GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor Atlanta, GA, July 31, 2024…
-
GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
GeoVax to Host Conference Call at 4:30 PM ET Atlanta, GA, July 30, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology…
-
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Company to discuss recent BARDA Project NextGen award for its next-generation COVID-19 vaccine and provide progress update across its clinical development pipeline …
-
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
Atlanta, GA, July 11, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…
-
GeoVax Provides First Half 2024 Business Update
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately…
-
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
10,000-participant randomized Phase 2b study will evaluate and compare GeoVax’s multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 Study is Funded by…
-
GeoVax to Present at BIO International Convention 2024
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® ATLANTA, GA, May 29, 2024 – GeoVax Labs, Inc.…
-
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1
10,000-participant randomized Phase 2b study will evaluate and compare GeoVax’s multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 under BARDA’s Clinical…
-
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
Atlanta, GA, May 17, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…
-
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad efficacy of the…